Ailani, J., Andrews, J. S., Rettiganti, M., & Nicholson, R. A. (2020). Impact of galcanezumab on total pain burden: Findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). Journal of headache and pain, 21(1), 123-9. https://doi.org/10.1186/s10194-020-01190-7
Citácia podle Chicago (17th ed.)Ailani, Jessica, J. Scott Andrews, Mallikarjuna Rettiganti, a Robert A. Nicholson. "Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-blind, Placebo-controlled Studies in Patients with Episodic or Chronic Migraine (EVOLVE-1, EVOLVE-2, and REGAIN Trials)." Journal of Headache and Pain 21, no. 1 (2020): 123-9. https://doi.org/10.1186/s10194-020-01190-7.
Citácia podľa MLA (8th ed.)Ailani, Jessica, et al. "Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-blind, Placebo-controlled Studies in Patients with Episodic or Chronic Migraine (EVOLVE-1, EVOLVE-2, and REGAIN Trials)." Journal of Headache and Pain, vol. 21, no. 1, 2020, pp. 123-9, https://doi.org/10.1186/s10194-020-01190-7.